|
研究编号
|
研究题目
|
人群
|
研究阶段
|
状态
|
|
CAIN457A2103
|
A Randomized Multiple–dose, Open Label Study to Determine the Absolute Bioavailability of a Subcutaneous Administration of AIN457 in Patients with Chronic Plaque Type Psoriasis
|
PsO
|
临床
II
期
|
完成
|
|
NCT01364389
|
A 2-week Single-blind, Randomized, 3-arm Proof of Concept Study of the Effects of AIN457 (Anti-IL17 Antibody), ACZ885 (Canakinumab, Anti-IL1b Antibody), or Corticosteroids in Patients With Polymyalgia Rheumatica, Followed by an Open Label Phase to Assess Safety and Long Term Efficacy
|
风湿性多肌痛
|
临床
II
期
|
终止
|
|
TrialTroveID-195065
|
Association Of HLA-DRB1 Alleles With Clinical Responses To The Anti-Interleukin-17A Monoclonal Antibody Secukinumab In a Cohort Of Patients With Active Rheumatoid Arthritis: An Exploratory Phase II Biomarker Study
|
RA
|
临床
II
期
|
完成
|
|
NCT01874340
REec-2013-0265
|
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients with Relapsing Multiple Sclerosis
|
MS
|
临床
II
期
|
终止
|
|
NCT01478360
|
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous Administration of Secukinumab (AIN457) in Patients with Asthma Not Adequately Controlled with Inhaled Corticosteroids and Long Acting Beta-agonists
|
哮喘
|
临床
II
期
|
终止
|
|
NCT01433250
|
An Open Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis.
|
MS
|
临床
II
期
|
终止
|
|
CAIN457F2208
NCT01426789
|
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
|
RA
|
临床
II
期
|
完成
|
|
CAIN457F2206
EudraCT Number: 2010-024516-34
NCT01359943
|
A Randomized, Double-blind, Placebo-controlled Study of Efficacy, Safety and Tolerability of Secukinumab at 12 Weeks Administered with an i.v. or s.c. Loading Regimen Compared to Placebo in Patients with Active Rheumatoid Arthritis Despite Treatment with Methotrexate
|
RA
|
临床
II
期
|
完成
|
|
CPJMR0092202
NCT01250171
|
A Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study of Intravenous ACZ885 or AIN457 in Dry Eye Syndrome
|
干眼
|
临床
II
期
|
完成
|
|
EudraCT Number: 2009-011622-34
NCT01169844
|
An Open Label Non-randomized Extension Study to Evaluate the Safety and Tolerability of AIN457 (Anti Interleukin-17 Monoclonal Antibody) in Patients with Psoriatic Arthritis
|
PsA
|
临床
II
期
|
完成
|
|
CAIN457A2209-EXT
NCT01109940
|
An Open Label, Non-randomized Extension Study to Evaluate the Safety and Tolerability of AIN457 (Anti Interleukin-17 Monoclonal Antibody) in Patients with Moderate to Severe Ankylosing Spondylitis
|
AS
|
临床
II
期
|
完成
|
|
CAIN457A2202E1
NCT01009281
|
A 52 Week Open Label Extension Study to Evaluate the Safety and Tolerability of AIN457 (Anti IL-17 Monoclonal Antibody) in Patients with Moderate to Severe Crohn's Disease
|
CD
|
临床
II
期
|
终止
|
|
B2201
CAIN457B2201
EudraCT number: 2009-011626-34
NCT01051817
TrialTroveID-117251
|
A Randomized, Multi-center, Double-blind, Proof-of-concept Study to Assess the Effect of Multiple Infusions of AIN457 (10 mg/kg) Versus Placebo on Disease Activity (MRI Scans) in Patients With Relapsing-remitting Multiple Sclerosis
|
MS
|
临床
II
期
|
完成
|
|
09-I-0175
090175
NCT00936585
TrialTroveID-111976
|
NIH SUBSTUDY:Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of Two Single Infusions of AIN457 in Patients With Moderate to Severe Active Crohn's Disease
|
CD
|
临床
II
期
|
终止
|
|
CAIN457A2212
NCT00805480
|
Phase II Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled Multiple-Loading Dose Regimen Study to Assess the Safety, Efficacy and Duration of Response of AIN457 in Patients with Chronic Plaque-Type Psoriasis.
|
PsO
|
临床
II
期
|
完成
|
|
EudraCT Number: 2008-002631-33
NCT00809159
|
Randomized, Placebo Controlled Double Blind, Multi-center Phase II Proof-of-concept Study to Assess the Efficacy of AIN457 in Patients With Moderate to Severe Ankylosing Spondylitis
|
AS
|
临床
II
期
|
完成
|
|
CAIN457A2104
NCT00920933
|
Double Blind, Placebo Controlled, Parallel Group Study with an Open Label Reference Arm to Assess the Effects of Intravenously Administered AIN457 on Ozone Induced Neutrophilia Compared to Placebo & Oral Corticosteroid in Healthy Volunteers
|
Ozone Induced Neutrophilia
|
临床
I/II
期
|
完成
|
|
CAIN457A2204
NCT00770965
|
Phase II Single Dose, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy of Three Dose Levels of AIN457 in Patients with Chronic Plaque-Type Psoriasis
|
PsO
|
临床
II
期
|
完成
|
|
HUM00017810
NCT00584740
|
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Two Single IV Infusions of AIN457 10 mg/kg (Anti IL-17 Monoclonal Antibody) in Patients with Moderate to Severe Active Crohn's Disease
|
CD
|
临床
II
期
|
终止
|
|
CAIN457A2102
NCT00669916
|
Phase 2a Single-Dose, Randomized, Double Blind, Multi-Center, Parallel-Group, Placebo-Controlled Proof of Concept Study to Assess the Efficacy, Safety, Tolerability, and Population Pharmacokinetics of AIN457 in Patients with Stable Plaque-Type Psoriasis
|
PsO
|
临床
I/II
期
|
完成
|
|
CAIN457A2101
NCT00669942
|
A Randomized, Double Blind, Placebo-Controlled, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients with Pharmacodynamics Assessed in an Expanded Cohort at the Maximum Tolerated Dose
|
RA
|
临床
I/II
期
|
完成
|
